prikaz prve stranice dokumenta NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis
  Download
PDF 4.37 MB
Scientific paper - Original scientific paper
NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis
Immunity, 48 (2018), 1; 107-119. https://doi.org/10.1016/j.immuni.2017.12.007
Glasner, Ariella; Levi, Assi; ...; Jonjić, Stipan; ...; Mandelboim, Ofer

Cite this document

Glasner, A., Levi, A., Jonjić, S. & Mandelboim, O. (2018). NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity, 48. (1), 107-119. doi: 10.1016/j.immuni.2017.12.007

Glasner, Ariella, et al. "NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis." Immunity, vol. 48, no. 1, 2018, pp. 107-119. https://doi.org/10.1016/j.immuni.2017.12.007

Glasner, Ariella, Assi Levi, Stipan Jonjić and Ofer Mandelboim. "NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis." Immunity 48, no. 1 (2018): 107-119. https://doi.org/10.1016/j.immuni.2017.12.007

Glasner, A., et al. (2018) 'NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis', Immunity, 48(1), pp. 107-119. doi: 10.1016/j.immuni.2017.12.007

Glasner A, Levi A, Jonjić S, Mandelboim O. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity [Internet]. 2018 January 16 [cited 2024 April 25];48(1):107-119. doi: 10.1016/j.immuni.2017.12.007

A. Glasner, A. Levi, S. Jonjić and O. Mandelboim, "NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis", Immunity, vol. 48, no. 1, pp. 107-119, January 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:184731. [Accessed: 25 April 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis
AuthorAriella Glasner
AuthorAssi Levi
Author
...
AuthorStipan Jonjić
Author
...
AuthorOfer Mandelboim
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Center for Proteomics)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Histology and Embryology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Natural killer (NK) cells are innate lymphoid cells, and their presence within human tumors correlates with better prognosis. However, the mechanisms by which NK cells control tumors in vivo are unclear. Here, we used reflectance confocal microscopy (RCM) imaging in humans and in mice to visualize tumor architecture in vivo.We demonstrated that signaling via the NK cell receptor NKp46 (human) and Ncr1 (mouse) induced interferon-g (IFN-g) secretion from intratumoral NK cells. NKp46- and Ncr1-mediated IFN-g production led to the increased expression of the extracellular matrix protein fibronectin 1 (FN1) in the tumors, which altered primary tumor architecture and resulted in decreased metastases formation. Injection of IFN-g into tumor-bearing mice or transgenic overexpression of Ncr1 in NK cells in mice resulted in decreased metastasis formation. Thus, we have defined a mechanism of NK cell-mediated control of metastases in vivo that may help develop NK cell-dependent cancer therapies.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleImmunity
Numberingvol. 48, no. 1, pp. 107-119
p-ISSN1074-7613
e-ISSN1097-4180
DOIhttps://doi.org/10.1016/j.immuni.2017.12.007
URN:NBNurn:nbn:hr:184:184731
Publication2018-01-16
ProjectNumber: 062-0621261-1263
Title (croatian): Molekularni mehanizmi citomegalovirusnog izmicanja imunološkom nadzoru
Leader: Stipan Jonjić
Jurisdiction: Croatia
Funding stream: ZP
ProjectNumber: 721317
Title (english): TIGIT therapy for cancer treatment
Acronym: TIGITtherapy
Jurisdiction: eu
Funding stream: H2020
Document URLhttps://doi.org/10.1016/j.immuni.2017.12.007
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2018-02-11 14:28:04